Skip to main content

2 Result(s)

within Paula I. Gonzalez-Ericsson Remove this filter Biomedicine Remove this filter

and

  1. Article

    Open Access

    PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer

    Clinical trials have demonstrated the efficacy of combining phosphoinositide 3-kinase (PI3K) inhibitors with endocrine therapies in hormone therapy-refractory breast cancer. However, biomarkers of PI3K pathway...

    Mellissa J. Nixon, Luigi Formisano, Ingrid A. Mayer… in npj Breast Cancer (2019)

    Download PDF (2172 KB) View Article

  2. No Access

    Article

    A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

    Checkpoint inhibitors produce durable responses in numerous metastatic cancers, but immune-related adverse events (irAEs) complicate and limit their benefit. IrAEs can affect organ systems idiosyncratically; p...

    Douglas B. Johnson, Wyatt J. McDonnell, Paula I. Gonzalez-Ericsson… in Nature Medicine (2019)